申请人:DAINIPPON SUMITOMO PHARMA CO., LTD.
公开号:US20140121243A1
公开(公告)日:2014-05-01
A medicament for treating diseases associated with cholinergic properties in the central nervous system (CNS) and/or peripheral nervous system (PNS), diseases associated with smooth muscle contraction, endocrine disorders, neurodegenerative disorders and the like, which comprises a compound of Formula (I):
wherein A is CR
1E
or a nitrogen atom, X—Y—Z is N—CO—NR
3A
R
3B
and the like, R
1A
to R
1E
are each independently a hydrogen atom and the like, R
2A
to R
2D
are each independently a hydrogen atom and the like, R
3A
and R
3B
are each independently an optionally-substituted C
3-10
cycloalkyl and the like, and n is 1 or 2
or a pharmaceutically acceptable salt thereof, which exhibits potent modulatory-effects on the activity of α7 nicotinic acetylcholine receptor (α7 nAChR).
一种用于治疗与中枢神经系统(CNS)和/或外周神经系统(PNS)中胆碱能特性相关疾病、与平滑肌收缩相关疾病、内分泌紊乱、神经退行性疾病等的药物,其中包括化合物Formula(I):其中A为CR1E或氮原子,X—Y—Z为N—CO—NR3AR3B等,R1A到R1E各自独立地为氢原子等,R2A到R2D各自独立地为氢原子等,R3A和R3B各自独立地为选择性取代的C3-10环烷基等,n为1或2或其药学上可接受的盐,具有对α7烟碱乙酰胆碱受体(α7 nAChR)活性的强效调节作用。